3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Unknown
1
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Neoplasms
5
Breast Neoplasms
4
Stomach Neoplasms
3
Malnutrition
3
Head and Neck Neoplasms
3
Colonic Neoplasms
3
Wilms Tumor
1
Sarcoma
1
Prostatic Neoplasms
1
Prostatic Intraepithelial Neoplasia
1
Peripheral Nervous System Diseases
1
Peptic Ulcer
1
Pancreatic Neoplasms
1
Osteoporosis
1
Neurotoxicity Syndromes
1
Neuroectodermal Tumors, Primitive, Peripheral
1
Myocardial Ischemia
1
Mucositis
1
Motor Activity
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, Extranodal NK-T-Cell
1
Lymphoma
1
Lung Neoplasms
1
Leukemia
1
Kidney Neoplasms
1
Inflammatory Bowel Diseases
1
Hyperphagia
1
Hepatitis C, Chronic
1
Hematologic Neoplasms
1
Heart Diseases
1
Interventions
Oxaliplatin
14
Fluorouracil
11
Capecitabine
9
Surveys and Questionnaires
8
Leucovorin
8
Irinotecan
8
Cisplatin
8
Bevacizumab
8
Standard of Care
5
Gemcitabine
5
Drug Therapy
4
S 1 (combination)
3
Radiotherapy
3
Nivolumab
3
Interviews as Topic
3
IFL protocol
3
Educational Status
3
Cyclophosphamide
3
Colonoscopy
3
Blood Specimen Collection
3
5,10-methylenetetrahydrofolic acid
3
trebananib
2
tivozanib
2
pembrolizumab
2
Taxes
2
Remote Patient Monitoring
2
Pemetrexed
2
Panitumumab
2
Ocoxin
2
N-(2-fluoro-4-((2-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)carbonylaminopyridin-4-yl)oxy)phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Gastrointestinal Neoplasms
×
Dietary Supplements
×
Clear all
NCT03445260
2021-09-02
PROGRESS
Hamilton Health Sciences Corporation
Phase NA
Completed
73 enrolled